This analysis examines the historical and forecast performance for Genzyme in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Genzyme’s performance against key rivals in the ethical pharmaceutical sector
Analyze how an anticipated increase in competition for the Gaucher’s treatment Cerezyme will drive therapeutic diversification
Assess the company’s steady expansion of revenues generated via the oncology market
